Suggested remit: To appraise the clinical and cost effectiveness of avacopan within its marketing authorisation for treating anti-neutrophil cytoplasmic antibody-associated vasculitis.
Status In progress
Process STA 2018
ID number 1581

Provisional Schedule

Expected publication 13 July 2022

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
19 February 2021 The Department for Health and Social Care has asked NICE to conduct an appraisal of avacopan for maintenance treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis. Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during late-August 2021 when we will write to you about how you can get involved. These timelines are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive submission.
19 February 2021 In progress. Topic is in progress
23 September 2020 - 21 October 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance